Skip to main content

Advertisement

SpringerLink
Log in

Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma

  • Published:
Pathology & Oncology Research

Abstract

Phosphatase of regenerating liver (PRL)-3 is involved in the metastasis of various tumors, but the expression of PRL-3 and its possible role in primary intrahepatic cholangiocarcinoma (ICC) has not been reported yet. In this study, we assessed the expression levels of PRL-3 by immunohistochemistry in 102 primary ICC samples, 62 matched lymph node metastases (LNM) and 102 adjacent normal liver tissues. Then we investigated the relationship between PRL-3 expression and clinicopathologic factors. Survival analysis was performed to determine the prognostic significance of PRL-3 expression in ICC. Immunochemistry results suggested PRL-3 expression was negative or weak in non-neoplastic intrahepatic bile ducts of adjacent liver tissue. In primary lesion and LNM high PRL-3 expression was frequently detected. Furthermore, the rate of high PRL-3 expression in LNM was higher than that in primary lesion (80.6% vs. 47.1%, P < 0.05). High expression of PRL-3 in primary tumors was significantly associated with TNM (P < 0.001), T stage (P < 0.001), vascular invasion (P = 0.002), and LNM (P < 0.001). Survival analysis results with Kaplan-Meier method and Cox proportional hazard model indicated high expression of PRL-3 was correlated with decreased overall survival and was an independent prognostic marker of overall survival. Thus, our results suggested high expression of PRL-3 was correlated with progression and metastasis of ICC and indicated negative prognostic impact. PRL-3 might serve as a novel prognostic marker for patients with ICC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

PRL-3:

phosphatase of regenerating liver-3

ICC:

intrahepatic cholangiocarcinoma

LNM:

lymph node metastasis

RR:

relative risk

CI:

confidence interval

References

  1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005) Cholangiocarcinoma. Lancet 366:1303–1314

    Article  PubMed  Google Scholar 

  2. Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33:1353–1357

    Article  CAS  PubMed  Google Scholar 

  3. Shaib Y, EI-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115–125

    Article  PubMed  Google Scholar 

  4. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA et al (2001) Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut 48:816–820

    Article  CAS  PubMed  Google Scholar 

  5. Mouzas IA, Dimoulios P, Vlachonikolis IG, Skordilis P, Zoras O, Kouroumalis E (2002) Increasing incidence of cholangiocarcinoma in Crete 1992–2000. Anticancer Res 22:3637–3641

    PubMed  Google Scholar 

  6. Okuda K, Nakanuma Y, Miyazaki M (2002) Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 17:1049–1055

    Article  PubMed  Google Scholar 

  7. Okuda K, Nakanuma Y, Miyazaki M (2002) Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment. J Gastroenterol Hepatol 17:1056–1063

    Article  CAS  PubMed  Google Scholar 

  8. Anderson CD, Pinson CW, Berlin J, Chari RS (2004) Diagnosis and treatment of cholangiocarcinoma. Oncologist 9:43–57

    Article  PubMed  Google Scholar 

  9. Nakagawa T, Kamiyama T, Kurauchi N, Matsushita M, Nakanishi K, Kamachi H, Kudo T et al (2005) Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 29:728–733

    Article  PubMed  Google Scholar 

  10. Yamamoto M, Takasaki K, Yoshikawa T (1999) Lymph node metastasis in intrahepatic cholangiocarcinoma. Jpn J Clin Oncol 29:147–150

    Article  CAS  PubMed  Google Scholar 

  11. Harada K, Masuda S, Hirano M, Nakanuma Y (2003) Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol 34:857–863

    Article  CAS  PubMed  Google Scholar 

  12. Shimonishi T, Miyazaki K, Kono N, Sabit H, Tuneyama K, Harada K, Hirabayashi J et al (2001) Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol 32:302–310

    Article  CAS  PubMed  Google Scholar 

  13. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A et al (2004) Protein tyrosine phosphatases in the human genome. Cell 117:699–711

    Article  CAS  PubMed  Google Scholar 

  14. Stoker AW (2005) Protein tyrosine phosphatases and signalling. J Endocrinol 185:19–33

    Article  CAS  PubMed  Google Scholar 

  15. van Huijsduijnen RH, Bombrun A, Swinnen D (2002) Selecting protein tyrosine phosphatases as drug targets. Drug Discov Today 7:1013–1019

    Article  Google Scholar 

  16. Zeng Q, Hong W, Tan YH (1998) Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun 244:421–427

    Article  CAS  PubMed  Google Scholar 

  17. Mohn KL, Laz TM, Hsu JC, Melby AE, Bravo R, Taub R (1991) The immediate-early growth response in regenerating liver and insulin-stimulated H-35 cells: comparison with serum-stimulated 3T3 cells and identification of 41 novel immediate-early genes. Mol Cell Biol 11:381–390

    CAS  PubMed  Google Scholar 

  18. Diamond RH, Cressman DE, Laz TM, Abrams CS, Taub R (1994) PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth. Mol Cel Biol 14:3752–3762

    CAS  Google Scholar 

  19. Werner SR, Lee PA, DeCamp MW, Crowell DN, Randall SK, Crowell PL (2003) Enhanced cell cycle progression and down regulation of p21Cip1/Waf1 by PRL tyrosine phosphatases. Cancer Lett 202:201–211

    Article  CAS  PubMed  Google Scholar 

  20. Matter WF, Estridge T, Zhang C, Belagaje R, Stancato L, Dixon J, Johnson B et al (2001) Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling. Biochem Biophys Res Commun 283:1061–1068

    Article  CAS  PubMed  Google Scholar 

  21. Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, Pallen CJ et al (2003) PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 63:2716–2722

    CAS  PubMed  Google Scholar 

  22. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE et al (2001) A phosphatase associated with metastasis of colorectal cancer. Science 294:1343–1346

    Article  CAS  PubMed  Google Scholar 

  23. Wu X, Zeng H, Zhang X, Zhao Y, Sha H, Ge X, Zhang M et al (2004) Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol 164:2039–2054

    CAS  PubMed  Google Scholar 

  24. Kato H, Semba S, Miskad UA, Seo Y, Kasuga M, Yokozaki H (2004) High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res 10:7318–7328

    Article  CAS  PubMed  Google Scholar 

  25. Qian F, Li YP, Sheng X, Zhang ZC, Song R, Dong W, Cao SX et al (2007) PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo. Mol Med 13:151–159

    CAS  PubMed  Google Scholar 

  26. Bardelli A, Saha S, Sager JA, Romans KE, Xin B, Markowitz SD, Lengauer C (2003) PRL-3 expression in metastatic cancers. Clin Cancer Res 9:5607–5615

    CAS  PubMed  Google Scholar 

  27. Miskad UA, Semba S, Kato H, Yokozaki H (2004) Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. Pathobiology 71:176–184

    Article  CAS  PubMed  Google Scholar 

  28. Miskad UA, Semba S, Kato H, Matsukawa Y, Kodama Y, Mizuuchi E, Maeda N et al (2007) High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch 450:303–310

    Article  CAS  PubMed  Google Scholar 

  29. Wang L, Peng L, Dong B, Kong L, Yan L, Xie Y, Shou C (2006) Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. Ann Oncol 17:1517–1522

    Article  CAS  PubMed  Google Scholar 

  30. Polato F, Codegoni A, Fruscio R, Perego P, Mangioni C, Saha S, Bardelli A et al (2005) PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res 11:6835–6839

    Article  CAS  PubMed  Google Scholar 

  31. Ren T, Jiang B, Xing X, Dong B, Peng L, Meng L, Xu H et al (2009) Prognostic Significance of Phosphatase of Regenerating Liver-3 Expression in Ovarian Cancer. Pathol Oncol Res (Epub ahead of print)

  32. Nakanuma Y, Sripa B, Vatanasapt V, Leong ASY, Ponchon T, Ishak KG (2000) Intrahepatic cholangiocarcinoma. In: Hamilton SR, Aaltonen LA (eds) World Health Organization classification of tumours: pathology and genetics of tumours of the digestive system. IARC Press, Lyon, pp 173–180

    Google Scholar 

  33. Junking M, Wongkham C, Sripa B, Sawanyawisuth K, Araki N, Wongkham S (2008) Decreased expression of galectin-3 is associated with metastatic potential of liver fluke-associated cholangiocarcinoma. Eur J Cancer 44:619–626

    Article  CAS  PubMed  Google Scholar 

  34. Peng L, Ning J, Meng L, Shou C (2004) The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol 130:521–526

    Article  CAS  PubMed  Google Scholar 

  35. Nichols JC, Gores GJ, LaRusso NF, Wiesner RH, Nagorney DM, Ritts RE Jr (1993) Diagnostic role of serum CA19–9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 68:874–879

    CAS  PubMed  Google Scholar 

  36. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ (2000) The utility of CA19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95:204–207

    Article  CAS  PubMed  Google Scholar 

  37. Paik KY, Jung JC, Heo JS, Choi SH, Choi DW, Kim YI (2008) What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol 23:766–770

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

The authors thank Dr. Chengyong Qin for his valuable proposals. The technical assistance of the Scientific Center of Shandong Provincial Hospital is also gratefully acknowledged.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Provincial Hospital Affiliated to Shandong University, 324 Jingwu Weiqi Road, Jinan, 250021, People’s Republic of China

    Yijun Xu, Hui Liu, Tao Li & Chengyong Qin

  2. Department of Clinical Laboratory, Jiangsu Cancer Hospital, 42 Baiziting Road, Nanjing, 210009, People’s Republic of China

    Mingchen Zhu

  3. Department of Gastroenterology, Jinan Central Hospital Affiliated to Shandong University, 105 Jiefang Road, Jinan, 250013, People’s Republic of China

    Shuhong Zhang

Authors
  1. Yijun Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mingchen Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shuhong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chengyong Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chengyong Qin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, Y., Zhu, M., Zhang, S. et al. Expression and Prognostic Value of PRL-3 in Human Intrahepatic Cholangiocarcinoma. Pathol. Oncol. Res. 16, 169–175 (2010). https://doi.org/10.1007/s12253-009-9200-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-009-9200-y

Keywords

Search

Navigation